Serum angiopoietin-1 level is increased in patients with Behçet's disease

Joint Bone Spine

Volumn 77, Issue 4, 2010, Pages 340-344

  Choe, Jung Yoon ^a   Park, Sung Hoon ^a   Kim, Seong Kyu ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Angiogenesis; Angiopoietin; Beh et's disease

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SKIN DEFECT; BEHCET SYNDROME; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BEHCET SYNDROME; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 77954624964     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.01.014     Document Type: Article

References (27)

1. Maruotti N., Cantatore F.P., Crivellato E., et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006, 21:557-566.
2. Drouart M., Saas P., Billot M., et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003, 132:158-162.
3. Fink A.M., Cauza E., Hassfeld W., et al. Vascular endothelial growth factor in patients with psoriatic arthritis. Clin Exp Rheumatol 2007, 25:305-308.
4. Maruotti N., Cantatore F.P., Nico B., et al. Angiogenesis in vasculitides. Clin Exp Rheumatol 2008, 26:476-483.
5. Cekmen M., Evereklioglu C., Er H., et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet's syndrome. Int J Dermatol 2003, 42:870-875.
6. Bozoglu E., Dinc A., Erdem H., et al. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Behçet's patients with venous thrombosis. Clin Exp Rheumatol 2005, 23(4 Suppl. 38):S42-S48.
7. Erdem F., Gündoĝdu M., Kiki I., et al. Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet's disease. Rheumatol Int 2005, 25:599-603.
8. Hamzaoui K., Chelbi H., Kamoun M., et al. Increased endothelin-1 levels of BAL fluid in patients with Behçet's disease. Mediators Inflamm 2007, 2007:93726.
9. Hamzaoui A., Hamzaoui K., Chabbou A., et al. Endothelin-1 expression in serum and bronchoalveolar lavage from patients with active Behçet's disease. Br J Rheumatol 1996, 35:357-358.
10. Morisada T., Kubota Y., Urano T., et al. angiopoietins and angiopoietin-like proteins in angiogenesis. Endothelium 2006, 13:71-79.
11. Papapetropoulos A., García-Cardeña G., Dengler T.J., et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999, 79:213-223.
12. Maisonpierre P.C., Suri C., Jones P.F., et al. angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60.
13. Calabrese L., Fleischer A.B. Thalidomide: current and potential clinical applications. Am J Med 2000, 108:487-495.
14. Hamuryudan V., Mat C., Saip S., et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:443-450.
15. Tabata C., Tabata R., Kadokawa Y., et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007, 179:708-714.
16. International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
17. Sakane T., Takeno M., Suzuki N., et al. Behçet's disease. N Engl J Med 1999, 341:1284-1291.
18. Zouboulis C.C., May T. Pathogenesis of Adamantiades-Behçet's disease. Med Microbiol Immunol 2003, 192:149-155.
19. Kobayashi M., Ito M., Nakagawa A., et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology 2000, 36:362-371.
20. Lakhanpal S., Tani K., Lie J.T., et al. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985, 16:790-795.
21. O'Duffy J.D. Vasculitis in Behçet's disease. Rheum Dis Clin North Am 1990, 16:423-431.
22. Jones P.F. Not just angiogenesis--wider roles for the angiopoietins. J Pathol 2003, 201:515-527.
23. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
24. DeBusk L.M., Chen Y., Nishishita T., et al. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor a-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003, 48:2461-2471.
25. Oh H., Takagi H., Suzuma K., et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999, 274:15732-15739.
26. Koutroubakis I.E., Xidakis C., Karmiris K., et al. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest 2006, 36:127-132.
27. Kuroda K., Sapadin A., Shoji T., et al. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001, 116:713-720.